Widefield Swept-Source OCT Angiography Metrics Associated with the Development of Diabetic Vitreous Hemorrhage: A Prospective Study.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
09 2021
Historique:
received: 08 11 2020
revised: 01 02 2021
accepted: 18 02 2021
pubmed: 2 3 2021
medline: 23 11 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

To investigate the association among widefield swept-source (SS) OCT angiography (OCTA) metrics and systemic parameters and vitreous hemorrhage (VH) occurrence in eyes with proliferative diabetic retinopathy (PDR). Prospective, observational study. Fifty-five eyes from 45 adults with PDR, with no history of VH, followed up for at least 3 months. All patients underwent widefield SS OCTA (Montage 15 × 15 mm and high-definition (HD)-51 line scan) imaging. Images were evaluated independently by 2 graders for quantitative and qualitative widefield SS OCTA metrics defined a priori. Systemic and ocular parameters and widefield SS OCTA metrics were screened using least absolute shrinkage and selection operator and logistic or Cox regression for variable selection. Firth's bias-reduced logistic regression models (outcome, occurrence of VH) and Cox regression models (outcome, time to occurrence of VH) were used to identify parameters associated with VH occurrence. Occurrence of VH. Over a median follow-up of 363 days (range, 28-710 days), 13 of 55 PDR eyes (24%) demonstrated VH during the follow-up period. Presence of extensive neovascularizations (odds ratio, 8.05; 95% confidence interval [CI], 1.43-58.56; P = 0.02), defined as neovascularizations with total area of more than 4 disc diameters, and forward neovascularizations (odds ratio, 5.42; 95% CI, 1.26-35.16; P = 0.02) that traversed the posterior hyaloid face into the vitreous were associated with the occurrence of VH. The presence of flat neovascularizations (odds ratio, 0.25; 95% CI, 0.04-1.01; P = 0.05) confined to the posterior hyaloid face was associated with a lower risk of VH with borderline significance. Similarly, presence of extensive neovascularizations (hazard ratio, 18.24; 95% CI, 3.51-119.47; P < 0.001) and forward neovascularizations (hazard ratio, 9.60; 95% CI, 2.07-68.08; P = 0.002) was associated significantly with time to development of VH. Widefield SS OCTA is useful for evaluating neovascularizations and their relationship with the vitreous. The presence of forward and extensive neovascularizations was associated with the occurrence of VH in patients with PDR. Larger samples and longer follow-up are needed to verify the risk factors and imaging biomarkers for diabetic VH.

Identifiants

pubmed: 33647282
pii: S0161-6420(21)00154-8
doi: 10.1016/j.ophtha.2021.02.020
pmc: PMC9055532
mid: NIHMS1800219
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1312-1324

Subventions

Organisme : NEI NIH HHS
ID : R01 EY027739
Pays : United States

Informations de copyright

Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmol Retina. 2019 Apr;3(4):350-361
pubmed: 31014688
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Am J Ophthalmol. 2020 Jul;215:72-80
pubmed: 32205122
Br J Ophthalmol. 2014 Jul;98(7):994-7
pubmed: 24659354
Retina. 2011 Nov;31(10):1983-7
pubmed: 21836531
Retina. 2017 Jul;37(7):1287-1296
pubmed: 27749694
Ophthalmology. 1991 May;98(5 Suppl):757-65
pubmed: 2062511
Eye (Lond). 2017 Apr;31(4):628-631
pubmed: 28009346
Ophthalmology. 2019 Dec;126(12):1675-1684
pubmed: 31358386
Br J Ophthalmol. 2022 Apr;106(4):534-539
pubmed: 33355148
Am J Ophthalmol. 2018 Aug;192:146-156
pubmed: 29806991
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6247-6255
pubmed: 27849310
Jpn J Ophthalmol. 2018 May;62(3):286-291
pubmed: 29460018
Am J Ophthalmol. 2019 Oct;206:154-160
pubmed: 31078541
JAMA. 1972 Jun 5;220(10):1354-5
pubmed: 4112318
Surv Ophthalmol. 1997 Jul-Aug;42(1):3-39
pubmed: 9265701
Transl Vis Sci Technol. 2019 Nov 15;8(6):18
pubmed: 31772829
Int J Ophthalmol. 2017 Mar 18;10(3):461-466
pubmed: 28393040
Br J Ophthalmol. 1980 Jul;64(7):469-71
pubmed: 7426560
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Int Ophthalmol Clin. 2014 Spring;54(2):141-53
pubmed: 24613890
Br J Ophthalmol. 2021 Apr;105(4):577-581
pubmed: 32591347
J Diabetes Investig. 2018 Jul;9(4):940-945
pubmed: 29265703
Retina. 2016 Jun;36(6):1132-42
pubmed: 26630315
Clin Exp Ophthalmol. 2016 May;44(4):260-77
pubmed: 26716602
Yonsei Med J. 2019 Jan;60(1):65-72
pubmed: 30554492
Surv Ophthalmol. 2019 Sep - Oct;64(5):679-693
pubmed: 30772364
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Int Ophthalmol. 2008 Feb;28(1):29-34
pubmed: 17619829

Auteurs

Ying Cui (Y)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China; Harvard Retinal Imaging Lab, Boston, Massachusetts.

Ying Zhu (Y)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts; Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan, China.

Edward S Lu (ES)

Harvard Retinal Imaging Lab, Boston, Massachusetts.

Rongrong Le (R)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts; Wenzhou Medical University Affiliated Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Inês Laíns (I)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts.

Raviv Katz (R)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts.

Jay C Wang (JC)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts; Retina and Vitreous Service, Yale Eye Center, Department of Ophthalmology, Yale School of Medicine, New Haven, Connecticut.

Itika Garg (I)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts.

Yifan Lu (Y)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts.

Rebecca Zeng (R)

Harvard Retinal Imaging Lab, Boston, Massachusetts; Boston University School of Medicine, Boston University, Boston, MA.

Dean Eliott (D)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Demetrios G Vavvas (DG)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Deeba Husain (D)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Joan W Miller (JW)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Leo A Kim (LA)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

David M Wu (DM)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

John B Miller (JB)

Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Harvard Retinal Imaging Lab, Boston, Massachusetts. Electronic address: John_miller@meei.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH